Abstract 231P
Background
In the randomized, double-blind, phase 3 trial SOLO1, olaparib (OLA) in the maintenance setting demonstrated a 70% lower risk of disease progression or death than placebo in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation. This study aimed to evaluate the cost-effectiveness of OLA maintenance therapy versus routine surveillance (RS) after response to first-line platinum-based chemotherapy in this population in Singapore.
Methods
A three-state partitioned survival model was developed to simulate the lifetime (50 years) incremental cost-effectiveness ratio (ICER) of OLA versus RS from a healthcare payer perspective. Progression-free and overall survival curves were estimated using data from SOLO1 and extrapolated beyond the trial period using parametric survival models. Any patient who remained progression-free at year 7 was assumed to be a long-term survivor and no longer at risk of progression. Mortality rates for this group were modelled on all-cause mortality from the general population adjusted for BRCA1/2 mutation status. These assumptions were validated with local clinicians. Health state utilities and adverse event frequencies were obtained from SOLO1. Drug costs were sourced from local public healthcare institutions. Healthcare resource usage and costs were based on local clinician input and publications. A 3% discount rate was applied to costs and outcomes. Deterministic and probabilistic sensitivity analyses (PSA) were performed to assess the robustness of results.
Results
The base-case analysis of OLA maintenance therapy versus RS resulted in an ICER of SGD17,326 per quality-adjusted life year (QALY) gained. The ICER was most sensitive to variations in the discount rate and mortality risk in long-term survivors. PSA demonstrated that OLA was associated with an 81% probability of being cost-effective at a willingness-to-pay threshold of SGD50,000 per QALY gained.
Conclusions
OLA has a high potential of being a cost-effective maintenance therapy versus RS for patients with BRCA1/2 mutated advanced ovarian cancer after response to first-line chemotherapy in Singapore.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca Singapore Pte Ltd.
Funding
AstraZeneca Singapore Pte Ltd.
Disclosure
D.S. Tan: Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Roche; Honoraria (self): MSD; Honoraria (self): Bayer; Honoraria (self): Genmab; Honoraria (self): Tessa Therapeutics; Honoraria (self): Merck Serono ; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Karyopharm Therapeutics; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Roche (Foundation Medicine); Research grant / Funding (self): National Medical Research Council Singapore Clinician Scientist Award; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Bayer; Advisory / Consultancy: ETC/D3 Singapore; Advisory / Consultancy: Tessa Therapeutics; Advisory / Consultancy: Genmab. J.J. Chan: Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Merck Sharp & Dohme; Advisory / Consultancy: Eisai; Advisory / Consultancy: Pfizer; Research grant / Funding (institution): OncoQuest Inc; Research grant / Funding (institution): Pfizer; Travel / Accommodation / Expenses: Synthon; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Celgene. J.K. Loke: Full / Part-time employment: AstraZeneca. R. Hettle: Full / Part-time employment: AstraZeneca. C.C. Yu: Full / Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract